Akiko Sekiya1, Tomoe Hayashi2, Yasuko Kadohira3, Masami Shibayama4, Tomohide Tsuda5, Xiuri Jin5, Haruka Nomoto1, Hidesaku Asakura3, Takashi Wada4,6, Shigeki Ohtake1, Eriko Morishita1. 1. 1 Department of Clinical Laboratory Science, Kanazawa University Graduate School, Kodatsuno, Kanazawa, Ishikawa, Japan. 2. 2 Department of Hematology, Kanazawa City Hospital, Heiwa-machi, Kanazawa, Ishikawa, Japan. 3. 3 Department of Internal Medicine (III), Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan. 4. 4 Department of Clinical Laboratory, Kanazawa University Hospital, Takara-machi, Kanazawa, Ishikawa, Japan. 5. 5 Shino-Test Corporation, Oonodai, Minami-ku, Sagamihara, Kanagawa, Japan. 6. 6 Division of Nephrology, Department of Laboratory Medicine, Kanazawa University, Takara-machi, Kanazawa, Ishikawa, Japan.
Abstract
INTRODUCTION: Careful monitoring of the hypercoagulable state is required during pregnancy. However, coagulation and fibrinolysis markers are not fully utilized because there are no reference values reflective of coagulation and fibrinolysis dynamics during pregnancy, which differ from the nonpregnant state. METHODS: Changes in antithrombin (AT), fibrinogen (Fbg), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), soluble fibrin (SF), D-dimer (DD), and protein S (PS) were investigated in healthy pregnant women, and reference ranges in the early, mid, late, and end stages of pregnancy were established. RESULTS: The AT was essentially constant throughout pregnancy. The Fbg, F1+2, TAT, and DD increased significantly as pregnancy progressed. In contrast, SF did not show a significant increase throughout the entire pregnancy period. Total PS antigen and total PS activity showed a corresponding decrease from early gestation. When test data in 3 cases in which deep vein thrombosis or intrauterine fetal death occurred during pregnancy were compared to the established reference ranges, all of the cases had multiple markers with values that exceeded the reference ranges. CONCLUSION: Establishing reference ranges for each week could potentially make it possible to evaluate abnormalities of the coagulation and fibrinolysis systems during pregnancy. Of note, SF might be a useful marker that reflects thrombus formation during pregnancy. Larger-scale studies will be required to establish reference ranges for every gestational week.
INTRODUCTION: Careful monitoring of the hypercoagulable state is required during pregnancy. However, coagulation and fibrinolysis markers are not fully utilized because there are no reference values reflective of coagulation and fibrinolysis dynamics during pregnancy, which differ from the nonpregnant state. METHODS: Changes in antithrombin (AT), fibrinogen (Fbg), prothrombin fragment 1+2 (F1+2), thrombin-antithrombin complex (TAT), soluble fibrin (SF), D-dimer (DD), and protein S (PS) were investigated in healthy pregnant women, and reference ranges in the early, mid, late, and end stages of pregnancy were established. RESULTS: The AT was essentially constant throughout pregnancy. The Fbg, F1+2, TAT, and DD increased significantly as pregnancy progressed. In contrast, SF did not show a significant increase throughout the entire pregnancy period. Total PS antigen and total PS activity showed a corresponding decrease from early gestation. When test data in 3 cases in which deep vein thrombosis or intrauterine fetal death occurred during pregnancy were compared to the established reference ranges, all of the cases had multiple markers with values that exceeded the reference ranges. CONCLUSION: Establishing reference ranges for each week could potentially make it possible to evaluate abnormalities of the coagulation and fibrinolysis systems during pregnancy. Of note, SF might be a useful marker that reflects thrombus formation during pregnancy. Larger-scale studies will be required to establish reference ranges for every gestational week.
Authors: Gaurav Girdhar; Samantha Ubl; Reza Jahanbekam; Sinduja Thinamany; Anna Belu; John Wainwright; Michael F Wolf Journal: eNeurologicalSci Date: 2019-01-08
Authors: Lucia Stanciakova; Miroslava Dobrotova; Pavol Holly; Jana Zolkova; Lubica Vadelova; Ingrid Skornova; Jela Ivankova; Matej Samos; Tomas Bolek; Marian Grendar; Jan Danko; Peter Kubisz; Jan Stasko Journal: Clin Appl Thromb Hemost Date: 2022 Jan-Dec Impact factor: 2.389
Authors: Gaurav Girdhar; Arielle Andersen; Elizabeth Pangerl; Reza Jahanbekam; Samantha Ubl; Kevin Nguyen; John Wainwright; Michael F Wolf Journal: J Biomed Mater Res A Date: 2018-09-22 Impact factor: 4.396